Citius Pharmaceuticals (NASDAQ:CTXR) Stock Breaks Above 50 Day Moving Average – Time to Sell?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s stock price passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.54 and traded as high as $0.55. Citius Pharmaceuticals shares last traded at $0.5411, with a volume of 201,092 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CTXR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, September 21st. Citigroup reiterated a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Finally, HC Wainwright reiterated a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

Citius Pharmaceuticals Trading Up 7.9%

The firm has a market capitalization of $14.85 million, a price-to-earnings ratio of -0.32 and a beta of 1.00. The business has a 50-day moving average of $0.54 and a two-hundred day moving average of $0.66. The company has a quick ratio of 0.40, a current ratio of 0.84 and a debt-to-equity ratio of 0.08.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. Research analysts predict that Citius Pharmaceuticals, Inc. will post -2.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

An institutional investor recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. bought a new position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned approximately 0.25% of Citius Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 16.88% of the stock is currently owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market.

Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place.